nach oben

Erschienen in:

01.07.2024 | Hämophilie | Leitlinie

Hämophilie-Behandlung in Österreich

verfasst von: Univ.-Prof. Dr. Christoph Male, MSc, Cihan Ay, Richard Crevenna, Sabine Eichinger, Clemens Feistritzer, Robert Füller, Alexander Haushofer, Andreas Kurringer, Peter Neumeister, Stephan Puchner, Thomas Rettl, Thomas Schindl, Gerhard Schuster, Gerhard Schwarz, Michael Sohm, Werner Streif, Katharina Thom, Barbara Wagner, Eva Wissmann, Karl Zwiauer, Ingrid Pabinger

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 4/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die vorliegende aktualisierte Leitlinie soll einen praxisnahen Leitfaden für die Diagnostik und Therapie von Personen mit Hämophilie (Persons with Haemophilia, PwH) in Österreich darstellen. In der Hämophilie-Therapie gibt es wenige vergleichende Interventionsstudien, daher haben die Empfehlungen einen meist niedrigen Evidenzgrad und beruhen auf einem Expertenkonsensus.

Als wesentliche Grundlage dieser Leitlinie dienen die internationalen Guidelines der „World Federation of Hemophilia (WFH)“ aus dem Jahr 2020. Diese wurden den nationalen Gegebenheiten und Erfahrungen angepasst.

Behandelt werden Diagnostik und Verlaufskontrollen, medikamentöse sowie begleitende Therapieoptionen und Prophylaxe, weiters spezielle Aspekte bei Kindern und Erwachsenen mit schwerer Hämophilie, Messung von Outcomes, die Vorgehensweise bei Traumen, speziellen Blutungen und Eingriffen einschließlich Zahnextraktionen, das Thema Hemmkörper sowie mögliche Probleme bei Konduktorinnen und psychosoziale Aspekte bei Hämophilie.

Pabinger I, Heistinger M, Muntean W, Reitter-Pfoertner SE, Rosenlechner S, Schindl T, Schuster G, Streif W, Thom K, Male C. Hämophiliebehandlung in Österreich. Wien Klin Wochenschr 2015;127[Suppl 3]:115–130. https://doi.org/10.1007/s00508-015-0872-x.

Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26:1–158.PubMedCrossRef

WFH. Report on the Annual Global Survey. 2022. https://elearning.wfh.org/resource/report-on-the-annual-global-survey-2022/.

Schulman S. Mild Hemophilia—Revised. Edition. 2012;(41). 2012 [2014/09/09]; Available from: http://www.wfh.org/en/page.aspx?pid=1270.

University College London. Factor VIII Variant Database. [2024-01-31]; Available from: http://www.factorviii-db.org/.

Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia. 2008;14(2):361–74.PubMedCrossRef

Endler G, Slavka G, Perkmann T, Haushofer A. [The importance of preanalytics for the coagulation laboratory]. Hämostaseologie. 2010;30(2):63–70. Epub 2010/05/11. Die Bedeutung der Praanalytik fur das Gerinnungslabor.

Knöbl P, Erworbene Hemmkörper-Hämophilie SM. Ligatur-Verlag. 2009. ISBN 978-3-940407-19‑1.

Wissenschaftlicher Beirat der Österreichischen Hämophilie Gesellschaft. Konsensus über die Verwendung von Faktorenkonzentraten bei Patienten mit Hämophilie (Version v. Nov. 2020). Available from: https://bluter.at/wp/wp-content/uploads/2021/02/Konsensus-des-Wissenschaftlichen-Beirates-zur-Therapie-der-Haemophilie.pdf

10.

Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295–308.PubMedPubMedCentralCrossRef

11.

Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397:630–40.PubMedCrossRef

12.

Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22:487–98.PubMedCrossRef

13.

Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.PubMedCrossRef

14.

Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1‑4 studies. Blood 2021 Apr 22;137(16):2231–2242. https://doi.org/10.1182/blood.2020009217

15.

Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jiménez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Deb S, Niggli M, Chang T, Lehle M, Fijnvandraat K. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024;143:1355–1364.

16.

Swan D, Mahlangu J, Thachil J. Non-factor therapies for bleeding disorders: A primer for the general haematologist. EJHaem. 2022;3:584–95.PubMedPubMedCentralCrossRef

17.

Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013–25.PubMedCrossRef

18.

Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med. 2023;388(8):694–705.PubMedCrossRef

19.

Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706–18.PubMedCrossRef

20.

Coppens M, Pipe SW, Miesbach W, et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.; HOPE-B Investigators. Lancet Haematol. 2024 Apr;11(4):e265-e275.

21.

Miesbach W, Chowdary P, Coppens M, et al. Delivery of AAV-based gene therapy through haemophilia centres—A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia. 2021 Nov;27(6):967–973. https://doi.org/10.1111/hae.14420. Epub 2021 Sep 22.

22.

Miesbach W, Oldenburg J, Klamroth R, et al. Gene therapy of Hemophilia: Recommendations from the German, Austrian, and Swiss Society for Thrombosis and Haemostasis Research (GTH). Haemostaseologie. 2023;43(3):196–207. https://doi.org/10.1055/a-1957-4477.CrossRef

23.

AWMF-Leitlinie „Therapie angeborener thrombozytärer Erkrankungen“, AWMF-Register Nr. 086-004, Klasse: S2K, erhältlich unter http://www.awmf.org/leitlinien/detail/ll/086-004.html. Accessed 2024-01-31.

24.

Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia. 2008;14(4:671–84.CrossRef

25.

Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339(4):245–53.PubMedCrossRef

26.

van Galen KP, Engelen ET, Mauser-Bunschoten EP, et al. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev. 2019 Apr 19;4(4):CD011385. https://doi.org/10.1002/14651858.CD011385.pub3

27.

Ullah K, Mukhtar H, Khalid U, et al. Is Antifibrinolytic Therapy Effective for Preventing Hemorrhage in Patients with Hemophilia Undergoing Dental Extractions? A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221114862. https://doi.org/10.1177/10760296221114862.

28.

Giangrande PL, Wilde JT, Madan B, et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009;15(2:501–8.CrossRef

29.

Richards M, Williams M, Chalmers E, et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010;149(4):498–507.PubMedCrossRef

30.

Ljung R, Fischer K, Carcao M, al group INPH. Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. Thromb Haemost. 2016;115:913–20.PubMedCrossRef

31.

Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia. 2002;8(6):745–52.PubMedCrossRef

32.

S2k-Leitlinie Synovitis bei Hämophilie. Version 2.0. Stand 15. Jan. 2022. AWMF-Registernummer: 086-005. Abrufbar unter: http://www.awmf.org/leitlinien/detail/ll/086-005.html. Accessed 2024-01-31.

33.

Stromer W, Pabinger I, Ay C, et al. Pain management in hemophilia: expert recommendations. WKWO 2021;133(19–20):1042–1056.

34.

Stromer W, Messerer B, Crevenna R, et al. Schmerztherapie bei Kindern und Jugendlichen mit Hämophilie. Handlungsempfehlungen einer Expertengruppe. Schmerz. 2018;32:404–18.PubMedCrossRef

35.

Taddio A, Ohlsson A, Einarson TR, et al. A systematic review of lidocaine-prilocaine cream (EMLA) in the treatment of acute pain in neonates. Pediatrics. 1998;101(2):E1. https://doi.org/10.1542/peds.101.2.e1.CrossRefPubMed

36.

World Federation of Hemophilia (WFH). Compendium of assessment tools. [2013/10/01]; Available from: http://www.wfh.org/en/page.aspx?pid=882.

37.

Gringeri A, Von Mackensen S. Quality of life in haemophilia. Haemophilia. 2008;14([Suppl3):19–25.PubMedCrossRef

38.

Konkle BA, Skinner M, Iorio A. Hemophilia trials in the twenty-first century: Defining patient important outcomes. Res Pract Thromb Haemost. 2019;3(2):184–92.PubMedPubMedCentralCrossRef

39.

Fischer K, de Kleij P, Negrier C, et al. The association of haemophilic arthropathy with Health-Related Quality of Life: a post hoc analysis. Haemophilia. 2016;22(6):833–40.PubMedCrossRef

40.

Njidam A, Foppen W, van der Schouw YT, et al. Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia. 2016;22:852–8.CrossRef

41.

Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–44.PubMedCrossRef

42.

Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010;16(2):256–62. Mar.PubMedCrossRef

43.

Auerswald G, Kurnik K, Aledort LM, et al. EPIC clinical study group. The EPIC study: a lesson to learn. Haemophilia. 2015;21(5):622–8. Sep.PubMedCrossRef

44.

Gouw SC, van der Bom JG, van den Berg MH. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;1;109(11):4648–54. Jun.PubMedCrossRef

45.

Pipe SW, Collins PW, Dhalluin C, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood. 2023 Dec 21:blood.2023021832. https://doi.org/10.1182/blood.2023021832.

46.

Mancuso ME, Male C, Kenet G, et al. Prophylaxis in children with haemophilia in an evolving treatment landscape. Haemophilia. 2021; https://doi.org/10.1111/hae.14412.CrossRefPubMedPubMedCentral

47.

Carpenter SL, Soucie JM, Presley RJ, et al. Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: a universal data collection database analysis. Haemophilia. 2015;21(1):e39–43.PubMedCrossRef

48.

Kroger AT, Atkinson WL, Pickering LK. 8—General immunization practices. In: Offit PA, Plotkin SA, Orenstein WA, editors. Vaccines (Sixth Edition). London: W.B. Saunders; 2013. p. 88–112.

49.

Injektionsweg mit Fokus Injektion bei Blutungsneigung. https://www.rki.de/DE/Content/Infekt/Impfen/Stichwortliste/G/Injektionsort_Tabelle.pdf. Accessed 2024-01-31.

50.

Tiede A, Leise H, Horneff S, et al. Safety of intramuscular COVID-19 vaccination in patients with haemophilia. Haemophilia. 2022;28(5):687–93. Sep.PubMedCrossRef

51.

Pfrepper C, Holstein K, Königs C, et al. Hemophilia Board of the German, Austrian, Swiss Society on Thrombosis Hemostasis Research (GTH). Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia. Hamostaseologie. 2021;41(3):190–6. Jun.PubMedCrossRef

52.

Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia. 2004;10:134–46.PubMedCrossRef

53.

Thom KE, Hoelzenbein T, Jones N, et al. Arterio-venous shunts as venous access in children with haemophilia. Haemophilia. 2018;24:429–35.PubMedCrossRef

54.

Breakey VR, Ignas DM, Warias AV, et al. A pilot randomized control trial to evaluate the feasibility of an Internet-based self-management and transitional care program for youth with haemophilia. Haemophilia. 2014;20(6):784–93.PubMedCrossRef

55.

Mortensen LG, Strand AM, Almen L. Adherence to prophylactic haemophilic treatment in young patients transitioning to adult care: a qualitative review. Haemophilia. 2018;24(6):862–72.CrossRef

56.

Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia. 2009;15(5):1014–21.PubMedCrossRef

57.

Manco-Johnson MJ, Lundin B, Funk S, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal Thromb Haemost 2017;15(11):2115–2124.

58.

Nijdam A, Foppen W, De Kleijn P, et al. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. Thromb Haemost. 2016;115(5):931–8.PubMedCrossRef

59.

Holstein K, Batorova A, Carvalho M, et al. Current view and outcome of ITI therapy—A change over time? Thromb Res. 2016;148:38–44.PubMedCrossRef

60.

Khair K, Chalmers E, Flannery T, et al. Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study. Ther Adv Hematol. 2021;12:20406207211007058.PubMedPubMedCentralCrossRef

61.

Ghosh K, Jijina F, Mohanty D. Haematuria and urolithiasis in patients with haemophilia. Eur J Haematol. 2003;70(6):410–2.PubMedCrossRef

62.

Singleton T, Kruse-Jarres R, Leissinger C. Emergency department care for patients with hemophilia and von Willebrand disease. J Emerg Med. 2010;39(2):158–65.PubMedCrossRef

63.

Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–9. Nov.PubMedCrossRef

64.

Bajkin B, Dougall A. Current state of play regarding dental extractions in patients with haemophilia: Consensus or evidence-based practice? A review of the literature. Haemophilia. 2020;26(2):183–99. Mar.PubMedCrossRef

65.

Mancuso ME, Apte S, Hermans C. Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022. Haemophilia. 2022;28(S4):93–102.PubMedCrossRef

66.

van den Berg HM, Fischer K, Carcao M, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood. 2019;134:317–20.PubMedCrossRef

67.

Male C, Gretenkort N, Rafowicz A, et al. on behalf of the PedNet study group. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica. 2021;106:123–9.PubMedCrossRef

68.

van Velzen AS, Eckhardt CL, Peters M, et al. Intensity of factor VIII treatment and the development of inhibitors in non-severe in non-severe hemophilia A patients: results of the INSIGHT case-control study. J Thromb Haemost. 2017;15:1422–9.PubMedCrossRef

69.

Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Hemost. 2009;35(8):752–9.PubMedCrossRef

70.

Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546–51.PubMedCrossRef

71.

Rangarajan S, Austin S, Goddard NJ, et al. Consensus recommendations for the use of FEIBA^®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and nonorthopaedic surgery. Haemophilia. 2013;19(2:294–303.CrossRef

72.

Valentino LA, Cooper DL, Goldstein B. Surgical experience with rFVIIa (NovoSeven^®) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia. 2011;17(4:579–89.CrossRef

73.

Fachinformation NovoSeven. https://www.ema.europa.eu/en/documents/product-information/novoseven-epar-product-information_en.pdf.

74.

Fachinformation FEIBA. https://www.takeda-produkte.de/system/files/produkt-info/fachinformation-feiba-nf-500-e1000-e-pulver-und-losungsmittel-zur-herstellung-einer-injektionslosung.pdf.

75.

Fachinformation Cevenfacta. https://www.ema.europa.eu/en/documents/product-information/cevenfacta-epar-product-information_en.pdf.

76.

Collins P, Chalmers E, Alamelu J, et al. First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors’ Organisation Inhibitor and Paediatric Working Parties. Haemophilia. 2017;23(5):654–9. Sep.PubMedCrossRef

77.

Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335–44.

78.

Batsuli G, Zimowski KL, Tickle K, et al. Epub 2019 Aug 2. Haemophilia. 2019;25(5):789–96.PubMedCrossRef

79.

Holstein K, Albisetti M, Bidlingmaier C, et al. on behalf of the ‘Ständige Kommission Hämophilie’ (Haemophilia board) of the German, Austrian, Swiss Society for Thrombosis Haemostasis Research (GTH). Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A. Haemostaseologie 2020;40:561-571.

80.

Streif W, Knöfler R. Perinatal Management of Haemophilia. Haemostaseologie. 2020;40:226–32.

81.

https://www.gesundheit.gv.at/leben/eltern/schwangerschaft/info/schwangerschaftsabbruch. (accessed 2024-01-31)

Titel: Hämophilie-Behandlung in Österreich
verfasst von: Univ.-Prof. Dr. Christoph Male, MSc
Cihan Ay
Richard Crevenna
Sabine Eichinger
Clemens Feistritzer
Robert Füller
Alexander Haushofer
Andreas Kurringer
Peter Neumeister
Stephan Puchner
Thomas Rettl
Thomas Schindl
Gerhard Schuster
Gerhard Schwarz
Michael Sohm
Werner Streif
Katharina Thom
Barbara Wagner
Eva Wissmann
Karl Zwiauer
Ingrid Pabinger
Publikationsdatum: 01.07.2024
Verlag: Springer Vienna
Schlagwörter: Hämophilie
Antifibrinolytika
Erschienen in: Wiener klinische Wochenschrift / Ausgabe Sonderheft 4/2024
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-024-02370-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Hämophilie-Behandlung in Österreich

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Innere Medizin